Christel Vangestel

Citado por

	Total	Desde 2019
Citas	1285	709
Índice h	20	14
Índice i10	35	25

160

120

20102011201220132014201520162017201820192020202120222023202428 48 59 52 53 49 67 92 96 110 123 142 144 149 41

Acceso público

Ver todo

17 artículos

1 artículo

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Sigrid StroobantsDirección de correo verificada de uantwerpen.be
Filipe ElvasAssistant Professor, University of AntwerpDirección de correo verificada de uantwerpen.be
Koen AugustynsFull professor, Medicinal Chemistry, University of AntwerpDirección de correo verificada de uantwerpen.be
Sven De BruyckerLecturer at AP University of Applied Sciences and Arts AntwerpDirección de correo verificada de ap.be
Jeroen VerhaegheUniversity of AntwerpDirección de correo verificada de uantwerpen.be
Sara RapicDirección de correo verificada de uantwerpen.be
Chris ReutelingspergerEmeritus Professor of Biochemistry of Apoptosis, Department of Biochemistry, Maastricht UniversityDirección de correo verificada de maastrichtuniversity.nl
Filip LardonFull professor - Vice-rector, University of AntwerpDirección de correo verificada de uantwerpen.be
Wim MartinetLaboratory of Physiopharmacology, University of AntwerpDirección de correo verificada de uantwerpen.be
Guido De MeyerFull Professor of Pharmacology, University of AntwerpDirección de correo verificada de uantwerpen.be
Timon VandammeSenior consultant digestive and neuroendocrine oncology , University Hospital AntwerpDirección de correo verificada de uantwerp.be
Leo HoflandErasmus MCDirección de correo verificada de erasmusmc.nl
Wouter de HerderProfessor of endocrine Oncology, Erasmus University, ErasmusMC, Rotterdam, the NetherlandsDirección de correo verificada de erasmusmc.nl
Leclercq g.Ghent UniversityDirección de correo verificada de ugent.be
HH Boersma or Hendrikus BoersmaHospital PharmacistDirección de correo verificada de hetnet.nl
Philip ElsingaFull Professor in PET-Radiochemistry, University Medical Center GroningenDirección de correo verificada de umcg.nl
Jean PlumGhent university, belgiumDirección de correo verificada de ugent.be
Bart VandekerckhoveGhent UniversityDirección de correo verificada de ugent.be
Yves D'AsselerDepartment of Nuclear Medicine, Ghent UniversityDirección de correo verificada de UGent.be
wim ceelenGhent University HospitalDirección de correo verificada de ugent.be

Seguir

Christel Vangestel

Postdoctoral fellowship, University Hospital Antwerp, University of Antwerp

Dirección de correo verificada de uantwerpen.be

oncology nuclear medicine apoptosis hypoxia proliferation


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Molecular imaging of hypoxia with radiolabelled agents G Mees, R Dierckx, C Vangestel, C Van de Wiele European journal of nuclear medicine and molecular imaging 36, 1674-1686, 2009	246	2009
Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors T Vandamme, M Beyens, KO de Beeck, F Dogan, PM van Koetsveld, ... British journal of cancer 114 (6), 650-658, 2016	87	2016
Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA^5m chelators ES Moon, F Elvas, G Vliegen, S De Lombaerde, C Vangestel, ... EJNMMI radiopharmacy and chemistry 5, 1-20, 2020	74	2020
ATG4B inhibitors with a benzotropolone core structure block autophagy and augment efficiency of chemotherapy in mice A Kurdi, M Cleenewerck, C Vangestel, S Lyssens, W Declercq, ... Biochemical pharmacology 138, 150-162, 2017	68	2017
99mTc-(CO) 3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab C Vangestel, C Van de Wiele, N Van Damme, S Staelens, P Pauwels, ... Journal of Nuclear Medicine 52 (11), 1786-1794, 2011	53	2011
Characterization of [^99mTc]Duramycin as a SPECT Imaging Agent for Early Assessment of Tumor Apoptosis F Elvas, C Vangestel, S Rapic, J Verhaeghe, B Gray, K Pak, S Stroobants, ... Molecular imaging and biology 17, 838-847, 2015	49	2015
Development of a novel antibody–tetrazine conjugate for bioorthogonal pretargeting A Maggi, E Ruivo, J Fissers, C Vangestel, S Chatterjee, J Joossens, ... Organic & biomolecular chemistry 14 (31), 7544-7551, 2016	48	2016
In vivo imaging of apoptosis in oncology: an update C Vangestel, M Peeters, G Mees, R Oltenfreiter, HH Boersma, PH Elsinga, ... Molecular imaging 10 (5), 7290.2010. 00058, 2011	48	2011
99mTc-Duramycin SPECT imaging of early tumor response to targeted therapy: a comparison with 18F-FDG PET F Elvas, J Boddaert, C Vangestel, K Pak, B Gray, S Kumar-Singh, ... Journal of Nuclear Medicine 58 (4), 665-670, 2017	43	2017
Development of antibody immuno-PET/SPECT radiopharmaceuticals for imaging of oncological disorders—an update J Dewulf, K Adhikari, C Vangestel, TVD Wyngaert, F Elvas Cancers 12 (7), 1868, 2020	38	2020
Forcing cancer cells to commit suicide C Vangestel, C Van de Wiele, G Mees, M Peeters Cancer Biotherapy and Radiopharmaceuticals 24 (4), 395-407, 2009	37	2009
Early prediction of tumor response to treatment: preclinical validation of 99mTc-duramycin F Elvas, C Vangestel, K Pak, P Vermeulen, B Gray, S Stroobants, ... Journal of Nuclear Medicine 57 (5), 805-811, 2016	34	2016
Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl His-annexin A5 in a colorectal … C Vangestel, C Van de Wiele, G Mees, K Mertens, S Staelens, ... Molecular imaging 11 (2), 7290.2011. 00034, 2012	33	2012
Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator T Van Den Broeck, F Stevenaert, S Taveirne, V Debacker, C Vangestel, ... Blood, The Journal of the American Society of Hematology 112 (13), 5046-5051, 2008	30	2008
Evaluation of [¹⁸F]CP18 as a Substrate-Based Apoptosis Imaging Agent for the Assessment of Early Treatment Response in Oncology S Rapic, C Vangestel, F Elvas, J Verhaeghe, TV den Wyngaert, L Wyffels, ... Molecular Imaging and Biology 19, 560-569, 2017	25	2017
Pharmacologic activation of tumor hypoxia: a means to increase tumor 2-deoxy-2-[18F] fluoro-D-glucose uptake? G Mees, R Dierckx, C Vangestel, D Laukens, N Van Damme, ... Molecular imaging 12 (1), 49-58, 2013	25	2013
FDG uptake in primary squamous cell carcinoma of the head and neck P Deron, C Vangestel, I Goethals, A De Potter, M Peeters, H Vermeersch, ... Nuklearmedizin-NuclearMedicine 50 (01), 15-21, 2011	25	2011
18F-Flortanidazole hypoxia PET holds promise as a prognostic and predictive imaging biomarker in a lung cancer xenograft model treated with metformin and radiotherapy S De Bruycker, C Vangestel, T Van den Wyngaert, P Pauwels, S Staelens, ... Journal of Nuclear Medicine 60 (1), 34-40, 2019	24	2019
In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells C Vangestel, M Peeters, R Oltenfreiter, Y D'Asseler, S Staelens, ... Nuclear medicine and biology 37 (8), 965-975, 2010	23	2010
Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using ¹⁸F-FDG PET/CT for Monitoring Treatment Response R Capistrano, C Vangestel, A Wouters, Y Dockx, P Pauwels, S Stroobants, ... Cancer Biotherapy and Radiopharmaceuticals 31 (3), 99-109, 2016	22	2016

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores